You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

Laekna's New Drug Application for LAE002 (afuresertib) accepted by China's NMPA

EIT Pharma's lonafarnib New Drug Application accepted for review by US FDA for chronic hepatitis D treatment

AcuCort publishes Phase IV study results on patient use of Zeqmelit oral film

SoftOx doses first patient in SIS-03 proof-of-concept trial

BSF secures exclusive global commercialisation partnership for ETSYL

Aureka Biotechnologies raises USD100m to build biological world model for drug discovery

Kodiak Sciences enrols first patients in KSI-501 Phase 3 ALTO trial in patients with diabetic macular oedema

AbCellera reports positive Phase 2 results for menopause treatment ABCL635

Bristol Myers Squibb to invest USD2.3bn in Houston manufacturing campus

BeOne Medicines and Revolution Medicines expand oncology collaboration

Almirall partners with CrystalO to develop small molecules for medical dermatology

Sobi partners with Innate Pharma to advance lacutamab in T-cell lymphoma

Saniona grants AstronauTx worldwide rights to neurological disease programme

Oculis signs agreement to acquire Privosegtor from Accure Therapeutics

Biophytis receives Brazilian approval for Phase 2 obesity trial of BIO101

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026